These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26539004)

  • 41. High-grade endometrial stromal sarcoma following tamoxifen treatment.
    Engin H
    Gynecol Oncol; 2008 Jan; 108(1):253-4. PubMed ID: 17928038
    [No Abstract]   [Full Text] [Related]  

  • 42. Endometrial cancer within tamoxifen-related polyps in patients with breast cancer.
    Tate S; Yamazawa K; Sekiya S
    Acta Obstet Gynecol Scand; 2004 Aug; 83(8):769-70. PubMed ID: 15255851
    [No Abstract]   [Full Text] [Related]  

  • 43. [Changes in the endometrium in treatment of breast carcinoma with tamoxifen].
    Reslová T; Tosner J; Vávrová I; Resl M
    Ceska Gynekol; 1997 Oct; 62(5):277-9. PubMed ID: 9600168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist.
    MacMahon B
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-122-S1-39. PubMed ID: 9045310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Monitoring of postmenopausal women treated with tamoxifen for breast carcinoma].
    Epifani S; Lattarulo S; Maiorino R; Fabiano G
    G Chir; 2000; 21(6-7):310-2. PubMed ID: 10916956
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Endometrial cancer and tamoxifen. Discussion apropos of a series of cases].
    Sasco AJ; Ah-Song R; Gendre I; Zlatoff P; Bobin JY; Hallonet P; Leduc B
    Bull Cancer; 1997 Jan; 84(1):51-60. PubMed ID: 9180860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
    Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
    Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One step forward or one step back with tamoxifen?
    Gelmon K
    Lancet; 2000 Sep; 356(9233):868-9. PubMed ID: 11036885
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
    Cheng WF; Lin HH; Torng PL; Huang SC
    Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract]   [Full Text] [Related]  

  • 52. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P; Vergote I
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
    MacDonald KV; Bombard Y; Deal K; Trudeau M; Leighl N; Marshall DA
    Eur J Cancer; 2016 Jul; 61():85-93. PubMed ID: 27155447
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prescription pattern of Chinese herbal products that contain dang-qui and risk of endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan: a population-based study.
    Wu CT; Lai JN; Tsai YT
    PLoS One; 2014; 9(12):e113887. PubMed ID: 25485843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrence of endometrial cancer in a hysterectomised patient treated with tamoxifen for breast cancer: a case report.
    Woolas J; Davis M; Rahimi S
    J R Soc Med; 2020 Nov; 113(11):454-456. PubMed ID: 33044110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ACOG committee opinion. Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists.
    Int J Gynaecol Obstet; 1996 May; 53(2):197-9. PubMed ID: 8735304
    [No Abstract]   [Full Text] [Related]  

  • 57. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
    Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
    Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The breast cancer prevention trial: should women at risk take tamoxifen?
    McKeon VA
    J Obstet Gynecol Neonatal Nurs; 1999; 28(6 Suppl 1):34-8. PubMed ID: 10608495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.